SQI Receives Licenses to Sell RA Test in Canada; Expects FDA Clearance in 2009 | GenomeWeb
SQI Diagnostics, a Toronto-based developer of microarray-based tests, last week announced that Health Canada has granted it a license to begin selling an array-based panel for diagnosing and monitoring rheumatoid arthritis in Canada.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.